X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to helps Vaxxinity to work on the development of UB-311, which targets toxic forms of aggregated Aβ in the brain to fight Alzheimer disaease.
Lead Product(s): UB-311
Therapeutic Area: Neurology Product Name: UB-311
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Florida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
The collaboration aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting and to assess its effects on undisclosed proteins through in vitro and in vivo experiments, and animal models established by UCF.
Lead Product(s): Undisclosed
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Florida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2024
Details:
UB-312 is a vaccine candidate targeting pathological forms of alpha-synuclein (aSyn) for the disease-modifying treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies.
Lead Product(s): UB-312
Therapeutic Area: Neurology Product Name: UB-312
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
VXX-401 is an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9).
Lead Product(s): VXX-401
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VXX-401
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, designed to activate both B- and T-cell arms of the immune system directed against multiple structural viral antigens.
Lead Product(s): UB-612
Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Preclinically, UB-313 has shown strong immunogenicity across species, inducing anti-CGRP antibodies with similar properties as approved comparator monoclonal antibodies, as well as a favorable safety and tolerability profile.
Lead Product(s): UB-313
Therapeutic Area: Neurology Product Name: UB-313
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, which is designed to activate both B- and T-cell arms of the immune system directed against multiple structural viral antigens.
Lead Product(s): UB-612
Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
UB-311 is a fully synthetic vaccine candidate that employs the UBITh platform technologies to target aggregated forms of beta-amyloid in the brain to treat Alzheimer’s disease.
Lead Product(s): UB-311
Therapeutic Area: Neurology Product Name: UB-311
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Long Term Extension trials showed UB-311 to be well tolerated in mild-to-moderate AD patients over three years of repeat dosing, with a safety profile comparable to placebo and no cases of amyloid-related imaging abnormalities-edema (“ARIA-E”) in the main study.
Lead Product(s): UB-311
Therapeutic Area: Neurology Product Name: UB-311
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Outlines preliminary evidence suggesting UB-312 is well tolerated and induces dose-dependent antibody production, with high titer levels detectable in cerebrospinal fluid (CSF), a key characteristic for tackling diseases of the brain.
Lead Product(s): UB-312
Therapeutic Area: Neurology Product Name: UB-312
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
